Good MorningInvestor confidence was rattled on Tuesday when word of not one but two trials of COVID-19 vaccines was halted due to “adverse” events. The news triggered an early morning sell-off that had the major indices down about -0.50% when the opening bell sounded. While concerning, the news was largely shrugged off in favor of earnings from JP Morgan Chase and Citigroup. The nation’s two largest consumer banks reported better than expected results that foreshadow what could be a market-moving earnings season.
Revenue at both JP Morgan and Citigroup fell on a YOY period but came in above the consensus estimates. The most noteworthy detail in either report is that reserve-builds for credit losses were less than expected. In light of the current conditions, the slowdown in reserve-build was taken as a vote of confidence in the economic recovery. If the rest of the financial sector reports in like fashion a new all-time high is in store for the S&P 500.
Featured: Forget the million-dollar nest egg (Ad) 
|
Markets | |
Sometimes a company issues positive news and its stock price inexplicably goes down. Investors that take advantage of these situations can come out ahead when the market catches up with reality.
Last week GenMark Diagnostics (NASDAQ:GNMK) provided better than expected revenue guidance and announc... Read the Full Story |
|
From Our Partners | | In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the stock climbed 12,107 percent.
He called streaming video over Blockbuster in 1990 and flagged an obscure online bookshop named Amazon in 1996. Netflix rose 118,823 percent at its peak; Amazon is up 250,300 percent counting splits.
Gilder now points to three converging technologies he calls the Trillion Dollar Triangle, which he believes could outweigh those past breakthroughs combined. | | See the Trillion Dollar Triangle George Gilder is pointing at now |
|
Industrials | |
A Golden-Age For Fastenal?
I’ve heard (read I should say) that current conditions are a “golden age” for homebuilders. Pent-up demand, low inventory, streamlined businesses, and low-interest rates are combining in a way that means sustained, healthy business for the home builder... Read the Full Story |
|
Finance | | JPMorgan Chase & Co Is A Buy After Reporting Q3 Result
After reviewing the JPMorgan Chase & Co (NYSE:JPM) calendar Q3 earnings report and looking at the chart I cannot believe this stock is still trading at such a low valuation. Trading at only 17X this year’s consensus and 12X next i... Read the Full Story |
|
From Our Partners | | President Trump says America is building wealth again, and the U.S. Treasury calls the economy under his administration strong.
But markets still fluctuate, companies still miss expectations, and a major loss late in your career can be harder to recover from than one at age 40.
Physical gold offers protection that does not depend on market momentum, corporate earnings, or consumer spending. | | Download the free 2026 Wealth Preservation Guide to protect your retirement savings |
|
Healthcare | |
Admittedly, things weren't looking good for AstraZeneca (LON:AZN) for a while there. With good reason, too; its vaccine trials were stopped dead in their tracks when some truly disastrous side effects started showing up, and that might well have knocked the company out of the COVID-19 recovery sta... Read the Full Story |
|
Consumer Discretionary | | The Upgrades Are Already Rolling In For Levi Strauss
Levi Strauss (NYSE:LEVI) reported earnings about a week ago and blew away the consensus. The company proved that established brands with a healthy eCommerce presence are well-positioned for the pandemic. The company saw its revenue fall nearly 27... Read the Full Story |
|
From Our Partners | | Vincere licenses institutional-grade futures algorithms directly to individual investors — no nine-figure minimums, no PhD team required.
Your capital never leaves your U.S.-regulated brokerage or IRA. No leverage, no overnight positions, and the worst month in six years was -2.58 percent. No management fees or profit cuts — every dollar earned stays in your account.
Built by former hedge-fund quant researchers, Chicago-based and SEC-compliant, with a public team you can verify. | | See how the algorithm works inside your own brokerage account |
|
Technology | | Semiconductor equipment maker Kulicke and Soffa Industries (NASDAQ: KLIC) stock is an overlooked play on the surge in future semiconductor demand. Shares have underperformed the S&P 500 index (NYSEARCA: SPY) as peers are shaping up for a breakout. There’s no question the demand for semicon... Read the Full Story |
|
Technology | | The used car market has been very strong since the onset of the pandemic. There are several reasons for this strength, but a big piece of the puzzle has been a low new vehicle inventory. Automakers were forced to temporarily shut down for a couple of months earlier this year, which forced people tha... Read the Full Story |
|
Technology | | Cybersecurity firm CyberArk Software (NASDAQ: CYBR) shares have awoken but still trading below its pre-COVID levels in February. Shares are underperforming the benchmark S&P 500 index (NYSEARCA: SPY) and momentum peers in the cybersecurity space. Rather than chase the newcomers, prudent investor... Read the Full Story |
|
Technology | |
Whether you’re just beginning your journey as an investor with limited capital or you simply enjoy hunting for affordable stocks that can turn into lucrative investments, seeking out strong businesses that don’t have a hefty price tag can be a solid strategy. The truth is that you can ... Read the Full Story |
|
Technology | |
The business world moves at light speed these days. Many companies that once were known as industry leaders have had to adapt to new trends or face becoming irrelevant in the eyes of investors. Take IBM (NYSE:IBM) for example. It’s a business that was once the gold standard in the Informatio... Read the Full Story |
|
The Early Bird Stock Of The Day CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. | | View Today's Stock Pick |
|
